Measuring What Matters
The Journal of Clinical Psychiatry · 29.04.2026 · 87 (2)
DOI: 10.4088/jcp.25nr16047 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Clinical Psychiatry, online erschienen am 29.04.2026. Verfasst von Morgan Bron und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neurocrine Biosciences, Inc., San Diego, California. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Tetrabenazine, Tardive Dyskinesia, Valine.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurocrine Biosciences, Inc., San Diego, California.
- Corresponding Author: Morgan Bron, PharmD, MS, 12780 El Camino Real, San Diego, CA 92130 (mbron@neurocrine.com).
- Health Outcomes Solutions, Palm Beach Gardens, Florida.
- IQVIA, Durham, North Carolina.
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
- The Zucker Hillside Hospital; Glen Oaks, New York.
Zitieren
APA
Bron, M., Mathias, S. D., Stull, D. E., Zhang, H., Turner, M., Dunayevich, E., Parameswaran, A., Vanderhoef, D., Perez-Rodriguez, M. M., & Correll, C. U. (2026). Measuring What Matters. The Journal of Clinical Psychiatry, 87(2). https://doi.org/10.4088/jcp.25nr16047
Vancouver
Bron M, Mathias SD, Stull DE, Zhang H, Turner M, Dunayevich E, et al. Measuring What Matters. The Journal of Clinical Psychiatry. 2026;87(2). doi:10.4088/jcp.25nr16047
BibTeX
@article{Bron2026,
author = {Bron, Morgan and Mathias, Susan D and Stull, Donald E and Zhang, Hui and Turner, Michelle and Dunayevich, Eduardo and Parameswaran, Ashok and Vanderhoef, Dawn and Perez-Rodriguez, M Mercedes and Correll, Christoph U},
title = {Measuring What Matters},
journal = {The Journal of Clinical Psychiatry},
year = {2026},
volume = {87},
number = {2},
doi = {10.4088/jcp.25nr16047}
}
EUVIMED